|
|
|
Home >
Health Conditions > Diabetes > Rezulin
(troglitazone)
Rezulin (troglitazone) Parke-Davis (removed from US market)
Related Topics:
News & Research:
-
Insulin-sensitizing Drug Cut Diabetes Risk - Science Daily, 4/12/05 -
"troglitazone lowered diabetes onset by 75 percent"
-
Troglitazone Improves Endothelial Function And Fasting Plasma Insulin
Concentrations - Doctor's Guide, 3/4/03
-
Troglitazone Improves Cardiovascular Risk Factors Better Than Metformin In
Type 2 Diabetes - Doctor's Guide, 3/11/02
-
Troglitazone Augments Fatty Acid Flux Suppression By Insulin - Doctor's
Guide, 2/25/02
- Troglitazone Drug Helps
non-Diabetic Patients Lose Weight - Doctor's Guide, 6/20/01
- Troglitazone Improves
Ovulation And Hirsutism In Women With Polycystic Ovary Syndrome -
Doctor's Guide, 4/11/01
- Troglitazone Safe And
Effective In Triple Therapy - Doctor's Guide, 6/21/99
- Troglitazone Successful As
Combination Therapy For Diabetics - Doctor's Guide, 6/21/99
- FDA, Parke-Davis Urge
Limits On Rezulin Use - Doctor's Guide, 6/17/99
- Diabetes Drug Troglitazone
Slows Tumour Cells Growth - Doctor's Guide, 3/30/99
- FDA Panel Says Rezulin
Should Stay On Market - Doctor's Guide, 3/29/99
- Metformin/Troglitazone
Combination Improves Diabetes Control - Doctor's Guide, 3/25/98
- Rezulin Labeling Changes
Result Of Potential Liver Injury Risk - Doctor's Guide, 11/6/97
- Rezulin For Type II
Diabetes Cleared By FDA - Doctor's Guide, 1/30/97
- NIH Tests Rezulin as Part
of Prevention Study - Doctor's Guide, 1/30/97
Abstracts:
-
Thiazolidinedione (TZD) Use and Bone Loss in Older Diabetic Adults - J Clin
Endocrinol Metab. 2006 Apr 11 - "each year of TZD use
was associated with greater bone loss at the whole body (additional loss of
-0.61% per year; 95% CI: -1.02, -0.21% per year), lumbar spine (-1.23% per year;
95% CI: -2.06, -0.40% per year), and trochanter (-0.65% per year; 95% CI: -1.18,
-0.12% per year) in women, but not men, with diabetes"
Related Sites:
70526
|
|
